Carbidopa
Carbidopa is a tablet taken together with levodopa or carbidopa-levodopa to help treat the symptoms of Parkinson’s disease and related forms of parkinsonism, mainly by cutting down levodopa-related nausea and vomiting.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 9 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Carbidopa is a fine-tuning add-on to levodopa or carbidopa-levodopa for Parkinson’s disease and related parkinsonism, on the market since about 1982 and available generically, that blocks levodopa from turning into dopamine outside the brain so more reaches the brain with less nausea, though it does nothing for symptoms on its own. It is usually well tolerated itself, but because more levodopa gets through, involuntary movements (dyskinesias) can appear sooner, along with dizziness on standing and drowsiness. Watch above all for falling asleep without warning, even while driving. Never stop or cut back suddenly, since that has been linked to high fever, muscle stiffness and confusion.
Clinical pearls
- Take iron supplements or multivitamins with iron at a different time, since iron lowers absorption of carbidopa and levodopa.
- Vitamin B6 is fine here, because carbidopa stops B6 from undoing levodopa’s effect the way it would with levodopa alone.
- Remind any prescriber that metoclopramide, a common anti-nausea drug, and antipsychotics like risperidone can weaken Parkinson’s control.
- Before surgery with general anesthesia, ask the care team how to keep your Parkinson’s medicines going, since abrupt stops are risky.
Patient information guide A plain-language walkthrough of Carbidopa, written from its FDA label.
What Carbidopa is used for
▾
Carbidopa is an add-on medicine used with levodopa products. Uses include:
- Symptoms of idiopathic Parkinson’s disease (Carbidopa tablets and Lodosyn, oral tablets).
- Postencephalitic parkinsonism (Carbidopa tablets and Lodosyn).
- Symptomatic parkinsonism that may follow nervous system injury from carbon monoxide or manganese poisoning (Carbidopa tablets and Lodosyn).
- Added carbidopa for people whose carbidopa-levodopa provides too little carbidopa.
- Separate adjustment of carbidopa and levodopa in the occasional patient who needs it.
How Carbidopa works
▾
Parkinson’s symptoms are tied to low dopamine in the brain. Dopamine itself cannot get into the brain, but levodopa can, and it is turned into dopamine there.
Much levodopa is converted into dopamine in the body before reaching the brain, causing nausea. Carbidopa blocks that conversion outside the brain. More levodopa then reaches the brain, so lower levodopa doses can work.
Carbidopa dosage
▾
Carbidopa is a tablet taken by mouth with levodopa or carbidopa-levodopa. Your prescriber slowly adjusts the daily amount to find what works for you.
- Carbidopa tablets are scored so they can be split for small changes.
- If you are already on levodopa alone, your prescriber will plan a gap of at least twelve hours before starting.
- Do not stop or cut back suddenly without medical advice.
- A high-protein diet may reduce absorption in some people.
Dosing details from the FDA-approved label
From the Carbidopa prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- General dosing with carbidopa-levodopa or levodopa
- Optimal daily dosage must be determined by careful titration
- Most patients respond to a 1:10 proportion of carbidopa and levodopa, provided the daily dosage of carbidopa is 70 mg or more a day
- Maximum: The maximum daily dosage of carbidopa should not exceed 200 mg
- The amount of carbidopa in carbidopa-levodopa should be considered when calculating the total amount of carbidopa to be given each day.
- Patients receiving carbidopa-levodopa who require additional carbidopa
- 25 mg of carbidopa may be given with the first dose of carbidopa-levodopa each day
- Additional doses of 12.5 mg or 25 mg may be given during the day with each dose of carbidopa-levodopa
- Maximum: The maximum daily dosage of carbidopa, given as LODOSYN and as carbidopa-levodopa, should not exceed 200 mg
- For patients with inadequate reduction in nausea and vomiting when carbidopa is less than 70 mg a day and levodopa is less than 700 mg a day.
- Patients requiring individual titration of carbidopa and levodopa dosage
- Carbidopa initiated at 25 mg three or four times a day
- The two drugs are given at the same time, starting with no more than one-fifth (20%) to one-fourth (25%) of the previous or recommended daily dosage of levodopa when given without carbidopa
- In patients already receiving levodopa, at least twelve hours should elapse between the last dose of levodopa and initiation of carbidopa and levodopa.
- Dosage adjustment
- Dosage of carbidopa may be adjusted by adding or omitting one-half or one tablet a day
- Monitor closely during dose adjustment; involuntary movements may require dosage reduction.
Read the label’s full dosing text
DOSAGE AND ADMINISTRATION Whether given with carbidopa-levodopa or with levodopa, the optimal daily dose of carbidopa must be determined by careful titration. Most patients respond to a 1:10 proportion of carbidopa-levodopa, provided the daily dosage of carbidopa is 70 mg or more a day. The maximum daily dosage of carbidopa should not exceed 200 mg, since clinical experience with larger dosages is limited. If the patient is taking carbidopa-levodopa, the amount of carbidopa in carbidopa-levodopa should be considered when calculating the total amount of carbidopa to be administered each day. Patients Receiving Carbidopa-Levodopa Who Require Additional Carbidopa Some patients taking carbidopa-levodopa may not have adequate reduction in nausea and vomiting when the dosage of carbidopa is less than 70 mg a day, and the dosage of levodopa is less than 700 mg a day. When these patients are taking carbidopa-levodopa, 25 mg of carbidopa may be given with the first dose of carbidopa-levodopa each day. Additional doses of 12.5 mg or 25 mg may be given during the day with each dose of carbidopa-levodopa. Carbidopa may be given with any dose of carbidopa-levodopa as required for optimum therapeutic response. Carbidopa Tablets have functional scoring to facilitate the administration of 12.5 mg doses. The maximum daily dosage of carbidopa, given as carbidopa and as carbidopa-levodopa, should not exceed 200 mg. Patients Requiring Individual Titration of Carbidopa-levodopa Dosage Although carbidopa and levodopa is the most frequently used method of carbidopa-levodopa administration, there may be an occasional patient who requires individually titrated doses of these two drugs. In these patients, carbidopa should be initiated at a dosage of 25 mg three or four times a day. The two drugs should be given at the same time, starting with no more than one-fifth (20%) to one-fourth (25%) of the previous or recommended daily dosage of levodopa when given without carbidopa. In patients already receiving levodopa therapy, at least twelve hours should elapse between the last dose of levodopa and initiation of therapy with carbidopa and levodopa. A convenient way to initiate therapy in these patients is in the morning following a night when the patient has not taken levodopa for at least twelve hours.
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Carbidopa side effects
▾
Side effects mostly come from carbidopa being combined with levodopa. Common ones include:
Common side effects
- Involuntary movements (dyskinesias)
- Nausea
- Dizziness
- Drowsiness
- Confusion
- Headache
- Vomiting
- Low blood pressure on standing
When to get medical help
- Call your doctor right away if you have fever, severe muscle stiffness, confusion or sweating after your dose is lowered or stopped. These can signal a life-threatening reaction like neuroleptic malignant syndrome.
- Get help if you fall asleep suddenly during daily activities, including driving, or have significant daytime sleepiness.
- Tell your doctor about hallucinations, delusions, paranoia, depression or thoughts of suicide.
- Report new gambling urges, increased sex drive or other impulse control problems.
- Report worsening involuntary movements, which may mean your dose needs to be lowered.
- Seek care for fainting, chest pain, an irregular heartbeat, black or bloody stools, or signs of allergic reaction such as swelling or hives.
- Tell your doctor about seizures.
Seek help for sudden sleep episodes, hallucinations, depression or suicidal thoughts, fever with stiffness and confusion, fainting, or unusual urges like gambling.
Carbidopa warnings and precautions
▾
- Sudden sleep episodes: some people fall asleep without warning, including while driving. Avoid driving or risky activities if this happens.
- Stopping or cutting back suddenly: can cause high fever and confusion, similar to neuroleptic malignant syndrome.
- Involuntary movements: may appear sooner and at lower doses than with levodopa alone.
- No effect alone: carbidopa does not treat Parkinson’s on its own and does not reduce levodopa’s effects in the brain.
- Mood and behavior changes, including hallucinations, depression and impulse control problems, can occur.
Carbidopa interactions
▾
Several medicines can change how carbidopa and levodopa work or affect safety.
- Nonselective MAO inhibitors: must not be used together.
- Selegiline or rasagiline: may cause severe low blood pressure on standing.
- Blood pressure medicines: doses may need adjusting.
- Antipsychotics like phenothiazines and risperidone, isoniazid, phenytoin, papaverine: may reduce levodopa’s benefit.
- Iron salts and iron-containing multivitamins: lower absorption.
- Metoclopramide: may worsen Parkinson’s control.
- Tricyclic antidepressants: rare reports of high blood pressure and involuntary movements.
Interactions listed in the FDA-approved label
From the Carbidopa prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Antihypertensive drugs: Symptomatic postural hypotension has occurred when carbidopa, given with levodopa or carbidopa-levodopa combination products, was added to the treatment of a patient receiving antihypertensive drugs. Dosage adjustment of the antihypertensive drug may be required when carbidopa therapy is started.
- Monoamine oxidase inhibitors (Type A or B), including selegiline or rasagiline: Concomitant therapy with selegiline or rasagiline and carbidopa and carbidopa-levodopa may be associated with severe orthostatic hypotension not attributable to carbidopa-levodopa alone. See CONTRAINDICATIONS.
- Tricyclic antidepressants: There have been rare reports of adverse reactions, including hypertension and dyskinesia, with concomitant use of tricyclic antidepressants and carbidopa-levodopa preparations.
- Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid: May reduce the therapeutic effects of levodopa. Carefully observe patients for loss of therapeutic response.
- Phenytoin and papaverine: The beneficial effects of levodopa in Parkinson's disease have been reported to be reversed. Carefully observe patients for loss of therapeutic response.
- Iron salts or multivitamins containing iron salts: Iron salts can form chelates with levodopa and carbidopa and consequently reduce the bioavailability of carbidopa and levodopa. Coadminister with caution.
- Metoclopramide: May increase the bioavailability of levodopa by increasing gastric emptying, but may also adversely affect disease control by its dopamine receptor antagonistic properties.
Read the label’s full interactions text
Drug Interactions Caution should be exercised when the following drugs are administered concomitantly with LODOSYN (carbidopa) given with levodopa or carbidopa-levodopa fixed dose combination products. Symptomatic postural hypotension has occurred when LODOSYN, given with levodopa or carbidopa-levodopa combination products, was added to the treatment of a patient receiving antihypertensive drugs. Therefore, when therapy with LODOSYN, given with or without levodopa or carbidopa-levodopa combination products, is started, dosage adjustment of the antihypertensive drug may be required. For patients receiving monoamine oxidase inhibitors (Type A or B), (see CONTRAINDICATIONS ) . Concomitant therapy with selegiline or rasigiline and LODOSYN and carbidopa-levodopa may be associated with severe orthostatic hypotension not attributable to carbidopa-levodopa alone (see CONTRAINDICATIONS ). There have been rare reports of adverse reactions, including hypertension and dyskinesia, resulting from the concomitant use of tricyclic antidepressants and carbidopa-levodopa preparations. Dopamine D 2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa. In addition, the beneficial effects of levodopa in Parkinson’s disease have been reported to be reversed by phenytoin and papaverine. Patients taking these drugs with LODOSYN and levodopa or carbidopa-levodopa combination products should be carefully observed for loss of therapeutic response. LODOSYN and iron salts or multivitamins containing iron salts should be coadministered with caution. Iron salts can form chelates with levodopa and carbidopa and consequently reduce the bioavailability of carbidopa and levodopa. Although metoclopramide may increase the bioavailability of levodopa by increasing gastric emptying, metoclopramide may also adversely affect disease control by its dopamine receptor antagonistic properties.
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Carbidopa
▾
- Do not use if you are allergic to any ingredient.
- Levodopa products must not be used with narrow-angle glaucoma.
- Tell your prescriber if you take or recently took an MAO inhibitor.
- Mention sleep disorders or sedating medicines.
- Share all medicines you take, especially blood pressure drugs and iron supplements.
Carbidopa overdose
▾
No overdose reports with carbidopa have been received. Management is the same as for levodopa products: supportive care, gastric lavage, careful IV fluids, airway protection and heart monitoring for irregular rhythms. If you think too much was taken, get emergency help or call poison control right away.
What Carbidopa does in the body
▾
Carbidopa blocks the breakdown of levodopa into dopamine outside the brain. It does not readily enter the brain and has no obvious effects of its own at recommended doses. This means more levodopa reaches the brain and levodopa-related nausea and vomiting are less frequent, which can allow faster dose adjustment.
How your body processes Carbidopa
▾
With levodopa, carbidopa raises levodopa blood levels and lengthens its half-life. It cuts the amount of levodopa needed for a given effect by about 75%. Levodopa and carbidopa compete with certain amino acids for absorption, so a high-protein diet may reduce absorption in some people. Iron can also bind them and lower absorption.
How to store Carbidopa
▾
Store at 25°C (77°F), excursions permitted to 15 to 30°C (59 to 86°F) .
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Supplements & herbs that interact with Carbidopa
21 supplements and herbal products have documented interactions with Carbidopa in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 2
- Moderate · 10
- Minor · 9
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Nutrient depletion considerations
Carbidopa has been associated with lower levels of 1 nutrient in the clinical literature. This does not mean a deficiency will occur — it means these may be worth discussing with your pharmacist or healthcare provider, especially with long-term use.
Educational information from a licensed clinical database (Natural Medicines) — not medical advice. Do not start or stop medications or supplements without professional guidance.
Carbidopa: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Carbidopa — the kind of thing our pharmacy team would talk through with you at the counter.
What is carbidopa actually for?
▾
How should I take it?
▾
What side effects should I expect?
▾
Is it safe to drive on this medicine?
▾
What medicines or supplements should I watch out for?
▾
Does what I eat matter?
▾
Is Carbidopa available over the counter?
▾
When was Carbidopa first available?
▾
Who makes Carbidopa?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Carbidopa on HelloPharmacist
Carbidopa forms and strengths (how it comes)
Carbidopa is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Tablet
How this form is used
- Carbidopa tablets are used with carbidopa-levodopa or levodopa for Parkinson’s disease and related parkinsonism.
- Lodosyn is used with carbidopa-levodopa or levodopa for Parkinson’s disease and related parkinsonism.
- Lodosyn and Carbidopa tablets are used when carbidopa-levodopa provides too little carbidopa, or when carbidopa and levodopa need separate adjustment.
- Carbidopa tablets have functional scoring so doses can be adjusted by one-half tablet.
- Lodosyn is adjusted by your prescriber by adding or omitting a half or whole tablet per day.
- Lodosyn and Carbidopa tablets are given together with levodopa or carbidopa-levodopa, not alone.
- Lodosyn: if you are switching from levodopa alone, at least twelve hours should pass before starting with carbidopa.
Carbidopa on the U.S. market: products, makers and brands
How Carbidopa appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
9 companies list 9 Carbidopa product records with the FDA, mostly as tablet; the earliest marketing or approval year on record is 1975. Brand names on the directory include Lodosyn; the rest are generics.
Also listed with the FDA, not a patient dose form: Powder (17) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Carbidopa is used (Medicaid data)
A general measure of how commonly Carbidopa is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Carbidopa is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Carbidopa prescribed? Of the 1,601 medications we measure, Carbidopa ranks #1,381 by Medicaid prescriptions — more than 14% of them.
Utilization by Carbidopa product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
carbidopa 25 MG Oral Tablet
Summed across the 5 of 19 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 260260
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Carbidopa, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 5 of 19 listed Carbidopa NDCs with Medicaid activity.
Compare Carbidopa products
A representative set of FDA-listed product records for Carbidopa — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Tablet | ||||
| 25 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 25 mg | Oral | Bausch Health US, LLC | NDA | View NDC → |
| 25 mg | Oral | Edenbridge Pharmaceuticals LLC. | ANDA | View NDC → |
| 25 mg | Oral | Lupin Pharmaceuticals,Inc. | ANDA | View NDC → |
| 25 mg | Oral | NorthStar Rx LLC | ANDA | View NDC → |
| 25 mg | Oral | Novel Laboratories, Inc. | ANDA | View NDC → |
| 25 mg | Oral | Oceanside Pharmaceuticals | NDA AUTHORIZED GENERIC | View NDC → |
| 25 mg | Oral | Zydus Lifesciences Limited | ANDA | View NDC → |
| 25 mg | Oral | Zydus Pharmaceuticals USA Inc. | ANDA | View NDC → |
Showing 9 of 9 products — FDA National Drug Code Directory. See every product, package size and price: browse all 9 Carbidopa NDCs →
Carbidopa side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Carbidopa — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Carbidopa in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Carbidopa FDA approval history
How Carbidopa went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Carbidopa recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Carbidopa recalls since July 2021.
✅No Carbidopa recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 2019 1 dose form · 1 strength
-
Dose form (SCDF) Oral Tablet RxCUI 374941In current FDA listingsClinical drug / strength (SCD) 25 MGRxCUI 260260
Look up RxCUI 2019 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Carbidopa supply and shortage status
Whether Carbidopa is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
💵 What Carbidopa costs pharmacies (NADAC benchmark)
The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.
| Form | Strength | Pharmacy acquisition benchmark | |
|---|---|---|---|
| Tablet · Oral | 25 mg | $0.536 per tablet | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.
Carbidopa brand names
Carbidopa is sold under one brand name in the FDA directory — Lodosyn. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Carbidopa: manufacturers and labelers
9 companies list Carbidopa products with the FDA. By number of product records, the largest are Aurobindo Pharma Limited, Bausch Health US, LLC, Edenbridge Pharmaceuticals LLC.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Carbidopa drug class (RxNorm)
Carbidopa belongs to the Aromatic Amino Acid Decarboxylation Inhibitor class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Carbidopa page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Bausch Health US, LLC is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →